Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
AstraZeneca

Generated: July 21, 2019

DrugPatentWatch Database Preview

Patent: 10,233,245

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,233,245
Title:Methods of treating inflammatory and autoimmune diseases with natalizumab
Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn\'s Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Inventor(s): Lieberburg; Ivan (Berkeley, CA)
Assignee: BIOGEN MA INC. (Cambridge, MA)
Application Number:15/596,468
Patent Claims:see list of patent claims

Details for Patent 10,233,245

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up BIOGEN MA INC. (Cambridge, MA) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 10,233,245

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2007100770 Dec 11, 2008
World Intellectual Property Organization (WIPO) 2007100770 Sep 07, 2007
United States of America 2007207141 Sep 06, 2007
United States of America 2010196318 Aug 05, 2010
United States of America 2017022276 Jan 26, 2017
United States of America 2017247457 Aug 31, 2017
United States of America 9493567 Nov 15, 2016
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Daiichi Sankyo
McKinsey
Boehringer Ingelheim
US Department of Justice
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.